Core Insights - OneMedNet Corporation has announced a strategic partnership with ViuHealth to enhance its Real-World Data (RWD) offerings, particularly in the autoimmune disease sector [1][2] Group 1: Partnership Details - The partnership will integrate ViuHealth's longitudinal autoimmune disease data into OneMedNet's iRWD™ platform, which is powered by Palantir Foundry, thereby increasing the scale and diversity of regulatory-grade RWD [2][6] - ViuHealth will provide ongoing data that captures patient journeys, treatment adherence, flares, and outcomes, which will support pharmaceutical partners in drug discovery and market strategies [3][4] Group 2: Market Opportunity - The autoimmune therapeutics market is projected to exceed $166 billion globally in 2026, indicating a significant opportunity for pharmaceutical and biotechnology companies to leverage the enriched datasets for drug development and regulatory evidence [3][14] - Autoimmune diseases affect approximately 8% of the U.S. population, representing tens of millions of individuals, creating strong demand for longitudinal real-world data in life sciences and digital health [5][14] Group 3: Revenue Growth Strategy - This partnership is expected to drive OneMedNet's subscription revenue growth by integrating high-value, disease-specific data into the iRWD™ platform, making it more attractive for ongoing subscriptions rather than one-time sales [4][14] - The collaboration aims to create predictable Annual Recurring Revenue (ARR) and enhance customer retention through expanded data feeds [14] Group 4: Company Positioning - OneMedNet is positioning itself as a trusted data infrastructure provider in specialty disease areas, reinforcing its role in the rapidly growing real-world data and AI-enabled healthcare markets [7][8] - The company aims to build repeatable, subscription-oriented data partnerships that generate continuous data flows, enhancing its ability to deliver relevant cohorts reflecting real-world patient journeys [7][14]